<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580485</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 106385-102</org_study_id>
    <nct_id>NCT04580485</nct_id>
  </id_info>
  <brief_title>INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to&#xD;
      investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical&#xD;
      efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in&#xD;
      participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC,&#xD;
      ovarian cancer, CRPC, TNBC, or bladder cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Anticipated">July 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events (TEAE)</measure>
    <time_frame>Up to Approximately 28 months</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 90 days after last dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of INCB106385 as a single agent or in combination with INCMGA00012</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of INCB106385 as a single agent or in combination with INCMGA00012</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin of INCB106385 as a single agent or in combination with INCMGA00012</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Minimum observed plasma concentration over the dose interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of INCB106385 as a single agent or in combination with INCMGA00012</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of INCB106385 as a single agent or in combination with INCMGA00012</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Apparent oral dose clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Defined as the percentage of participants with a best overall response of CR or PR, as determined by investigator radiographic disease assessment according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Defined as the percentage of participants with a best overall response of CR, PR, or SD, as determined by investigator radiographic disease assessment according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Defined as the time from the earliest date of CR or PR until the earliest date of disease progression, as determined by investigator radiographic disease assessment according to RECIST v1.1, or death due to any cause if occurring sooner than progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumoral gene expression</measure>
    <time_frame>Predose and Week 5-6</time_frame>
    <description>Defined as the percent of patients with change in tumoral targeted gene expression compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immune cell activation in tumors</measure>
    <time_frame>Predose and Week 5-6</time_frame>
    <description>Defined as the percent of patients demonstrating change in immune cell activation in tumors compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Castration Resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Group A (TGA) - INCB106385</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 dose escalation, the dose levels will be escalated following a BOIN design.&#xD;
In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B (TGB) - INCB106385+INCMGA00012</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In part 1 dose escalation, the dose levels will be escalated following a BOIN design.&#xD;
In part 2 dose expansion, participants will be assigned to different groups based on their tumor types and treated at the RDE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB106385</intervention_name>
    <description>INCB106385 will be administered orally QD</description>
    <arm_group_label>Treatment Group A (TGA) - INCB106385</arm_group_label>
    <arm_group_label>Treatment Group B (TGB) - INCB106385+INCMGA00012</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCMGA00012</intervention_name>
    <description>INCMGA0012 will be administered IV once every 4 weeks (Q4W)</description>
    <arm_group_label>Treatment Group B (TGB) - INCB106385+INCMGA00012</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to comprehend and willingness to sign an ICF.&#xD;
&#xD;
          -  Willing and able to conform to and comply with all Protocol requirements.&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced/metastatic SCCHN, NSCLC, ovarian&#xD;
             cancer, TNBC, CRPC or bladder cancer that progressed after treatment with available&#xD;
             therapies (including anti PD-(L)1 therapy (if applicable).&#xD;
&#xD;
          -  Willingness to undergo pre- and on-treatment tumor biopsy.&#xD;
&#xD;
          -  Have CD8 T-cell-positive tumors.&#xD;
&#xD;
          -  Presence of measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  ECOG performance status 0 to 1.&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children based.&#xD;
&#xD;
          -  Acceptable laboratory parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cardiac disease.&#xD;
&#xD;
          -  Known or active CNS metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          -  Active or inactive autoimmune disease or syndrome that required systemic treatment in&#xD;
             the past 2 years or receiving systemic therapy for an autoimmune or inflammatory&#xD;
             disease..&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses&#xD;
             &gt; 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive&#xD;
             therapy within 7 days before the first dose of study treatment.&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment,or&#xD;
             history of other malignancy within 2 years of the first dose of study treatment.&#xD;
&#xD;
          -  Has not recovered to â‰¤ Grade 1 from toxic effects of prior therapy and/or&#xD;
             complications from prior surgical intervention before starting study treatment.&#xD;
&#xD;
          -  Evidence of interstitial lung disease, history of interstitial lung disease, or&#xD;
             active, noninfectious pneumonitis.&#xD;
&#xD;
          -  Immune-related toxicity during prior immune therapy for which permanent&#xD;
             discontinuation of therapy is recommended, or any immune-related toxicity requiring&#xD;
             intensive or prolonged immunosuppression to manage.&#xD;
&#xD;
          -  Any prior chemotherapy, biological therapy, or targeted therapy to treat the&#xD;
             participant's disease within 5 half-lives or 28 days (whichever is shorter) before the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          -  Any prior radiation therapy within 28 days before the first dose of study treatment.&#xD;
&#xD;
          -  Undergoing treatment with another investigational medication or having been treated&#xD;
             with an investigational medication within 5 half-lives or 28 days (whichever is&#xD;
             shorter) before the first dose of study treatment.&#xD;
&#xD;
          -  Concomitant treatment with strong CYP3A4 inhibitors or inducers.&#xD;
&#xD;
          -  Receipt of a live vaccine within 30 days of the first dose of study treatment.&#xD;
&#xD;
          -  Infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week&#xD;
             of the first dose of study treatment.&#xD;
&#xD;
          -  Evidence of HBV or HCV infection or risk of reactivation.&#xD;
&#xD;
          -  Known history of HIV (HIV 1/2 antibodies).&#xD;
&#xD;
          -  History of organ transplant, including allogeneic stem-cell transplantation.&#xD;
&#xD;
          -  Known hypersensitivity or severe reaction to any component of study drug(s) or&#xD;
             formulation components.&#xD;
&#xD;
          -  Inability to swallow food or any condition of the upper gastrointestinal tract that&#xD;
             precludes administration of oral medications.&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study.&#xD;
&#xD;
          -  Any condition that would, in the investigator's judgment, interfere with full&#xD;
             participation in the study,pose a significant risk to the participant; or interfere&#xD;
             with interpretation of study data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Gogov, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer de Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra (Cun)</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INCB106385</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

